Medical information Clinical review pending

Gynecological Testing

Maternal Serum Screen 2 Dual Test

The Maternal Serum Screen 2 Dual Test is a prenatal screening test performed between 9 and 13 weeks of pregnancy to assess the risk of certain chromosomal abnormalities, such as Down syndrome. It measures levels of PAPP-A and free Beta HCG in the mother's blood.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: 3 mL (1.5 mL minimum) serum collected in a Serum Separator Tube (SST).
Results: Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. However, provide accurate information regarding gestational age (LMP or ultrasound date), maternal age, number of fetuses, diabetic status, body weight, IVF history, smoking status, and any previous history of trisomy pregnancies.

Test priceKSh 5,031

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Maternal Serum Screen 2 Dual Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓First trimester prenatal screening
✓Risk assessment for Down syndrome (Trisomy 21)
✓Risk assessment for Trisomy 18
✓Risk assessment for Trisomy 13
✓Screening for women aged 35 or older
✓Screening for women with risk factors (e.g., family history, IVF)

In plain language

What this test helps you understand

This test provides a risk assessment for common chromosomal abnormalities during the first trimester of pregnancy, allowing for informed decision-making regarding further diagnostic testing or management.

The Maternal Serum Screen 2 Dual Test is a prenatal screening test designed to help assess the risk of chromosomal abnormalities, including Down syndrome (Trisomy 21), in the developing fetus. This test is typically performed during the first trimester of pregnancy, between 9 and 13 weeks gestation, with the ideal window being 10 to 13 weeks. It measures the levels of two specific substances in the mother's blood: Pregnancy-Associated Plasma Protein A (PAPP-A) and free Beta Human Chorionic Gonadotropin (free Beta HCG). These markers, combined with the mother's age, provide a risk assessment for chromosomal conditions. This screening test is not diagnostic; it indicates whether further, more definitive testing might be recommended. Discuss the results and implications with your healthcare provider.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. However, provide accurate information regarding gestational age (LMP or ultrasound date), maternal age, number of fetuses, diabetic status, body weight, IVF history, smoking status, and any previous history of trisomy pregnancies.

Sample3 mL (1.5 mL minimum) serum collected in a Serum Separator Tube (SST).

MethodologyImmunoassay for the quantitative measurement of PAPP-A and free Beta HCG in maternal serum.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This is a screening test and does not provide a definitive diagnosis. Results can be influenced by factors such as inaccurate gestational dating, multiple gestations, and certain maternal conditions. False positives and false negatives can occur. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

The test is typically performed between 9 and 13 weeks of pregnancy, with the ideal window being 10 to 13 weeks.

The test measures levels of PAPP-A (Pregnancy-Associated Plasma Protein A) and free Beta HCG (Human Chorionic Gonadotropin) in the mother's blood.

No, this is a screening test. It assesses the risk of chromosomal abnormalities but does not provide a definitive diagnosis. Further testing may be recommended based on the results.

You will need to provide your date of birth, last menstrual period (LMP) or ultrasound date, number of fetuses, diabetic status, body weight, IVF history, smoking status, and any previous history of trisomy pregnancies.

If the results indicate a higher risk, your healthcare provider will discuss the implications and may recommend further diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS).

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp